Lipid Metabolism Disorders as Diagnostic Biosignatures in Sepsis
-
Published:2024-08-26
Issue:5
Volume:16
Page:806-819
-
ISSN:2036-7449
-
Container-title:Infectious Disease Reports
-
language:en
-
Short-container-title:Infectious Disease Reports
Author:
Birner Charlotte1, Mester Patricia1, Liebisch Gerhard2ORCID, Höring Marcus2ORCID, Schmid Stephan1ORCID, Müller Martina1, Pavel Vlad1ORCID, Buechler Christa1ORCID
Affiliation:
1. Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany 2. Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, 93053 Regensburg, Germany
Abstract
Critical illness causes disturbances in lipid metabolism. Here, we investigated the levels of apolipoprotein A-IV (apoA-IV), a regulator of triglyceride and cholesterol metabolism, in human sepsis. ApoA-IV (analyzed in 156 patients with systemic inflammatory response syndrome (SIRS)/sepsis) and cholesteryl ester (CE) (analyzed in 121 of these patients) were lower in patients compared to 43 healthy controls. In contrast, triglyceride (TG) levels were elevated in patients. ApoA-IV levels in plasma of the patients did not correlate with these lipids. Patients with SIRS, sepsis or septic shock had comparable apoA-IV, TG, CE and free cholesterol (FC) levels. Patients on dialysis had significantly lower CE levels, whereas apoA-IV levels did not change much. CE levels were elevated in patients with viral sepsis due to SARS-CoV-2 infection in comparison to SIRS/sepsis patients not infected by this virus. CE levels correlated negatively with procalcitonin, interleukin-6 and bilirubin, while TGs were positively associated with bilirubin and C-reactive protein. ApoA-IV, TG, CE and FC levels were not associated with bacterial infection or survival. In conclusion, this analysis suggests that CE levels decline in sepsis-related renal failure and also shows that plasma apoA-IV and CE levels are early biomarkers of sepsis.
Reference56 articles.
1. Apolipoproteins A-I and B: Biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease;Olofsson;Vasc. Health Risk Manag.,2007 2. Florea, G., Tudorache, I.F., Fuior, E.V., Ionita, R., Dumitrescu, M., Fenyo, I.M., Bivol, V.G., and Gafencu, A.V. (2022). Apolipoprotein A-II, a Player in Multiple Processes and Diseases. Biomedicines, 10. 3. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host;Khovidhunkit;J. Lipid Res.,2004 4. Kowalska, K., Sabatowska, Z., Forycka, J., Mlynarska, E., Franczyk, B., and Rysz, J. (2022). The Influence of SARS-CoV-2 Infection on Lipid Metabolism-The Potential Use of Lipid-Lowering Agents in COVID-19 Management. Biomedicines, 10. 5. Zhao, M., Luo, Z., He, H., Shen, B., Liang, J., Zhang, J., Ye, J., Xu, Y., Wang, Z., and Ye, D. (2021). Decreased Low-Density Lipoprotein Cholesterol Level Indicates Poor Prognosis of Severe and Critical COVID-19 Patients: A Retrospective, Single-Center Study. Front. Med., 8.
|
|